Trimetazidine: The future of cardiac function?

Future Cardiology

Volumn 5, Issue 5, 2009, Pages 421-424

  Di Napoli, Pericle ^a   Taccardi, Alfonso A ^a  

^a Heart Failure Unit   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOBUTAMINE; ENDOTHELIN 1; INOTROPIC AGENT; TRIMETAZIDINE; VASODILATOR AGENT;

AGING; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOMYOPATHY; CHRONIC DISEASE; DEVELOPING COUNTRY; DRUG EFFICACY; DRUG MECHANISM; EDITORIAL; FATTY ACID OXIDATION; GLUCOSE OXIDATION; HEART CONTRACTION; HEART FAILURE; HEART FUNCTION; HEART HEMODYNAMICS; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE METABOLISM; HEART PROTECTION; INSULIN RESISTANCE; MORBIDITY; MORTALITY; OXYGEN CONSUMPTION; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RISK FACTOR; RISK REDUCTION; STABLE ANGINA PECTORIS; HUMAN; PATHOPHYSIOLOGY;

HEART FAILURE; HUMANS; PROGNOSIS; TRIMETAZIDINE; VASODILATOR AGENTS;

EID: 70349213943     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/fca.09.26     Document Type: Editorial

References (30)

1. Kannel WB: Incidence and epidemiology of heart failure. Heart Fail. Rev. 5(2), 167-173 (2000).
2. Sliwa K, Damasceno A, Mayosi BM: Epidemiology and etiology of cardiomyopathy in Africa. Circulation 112(23), 3577-3583 (2005).
3. Stewart S, MacIntyre K, Hole DJ, Capewell S, McMurray JJV: More 'malignant' than cancer? Five-year survival following a first admission for heart failure. Eur. J. Heart Fail. 3(3), 315-322 (2001).
4. MERIT-HF Investigators: Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomized intervention Trial in congestive heart failure (MERIT-HF). Lancet 353(9169), 2001-2007 (1999).
5. Carson P, Anand I, O'Connor C et al.: Mode of death in advanced heart failure: the Comparison of Medical, Pacing, and Defibrillator Therapies in Heart Failure (COMPANION) Trial. J. Am. Coll. Cardiol. 46(12), 2329-2334 (2005).
6. Frenneaux MP: Autonomic changes in patients with heart failure and in post-myocardial infarction patients. Heart 90(11), 1248-1255 (2004).
7. Neubauer S: The failing heart: an engine out of fuel. N. Engl. J. Med. 356(11), 1140-1151 (2007).
8. Hunt SA, Abraham WT, Chin MH et al.: 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 119(14), E391-E479 (2009).
9. Di Napoli P, Barsotti A: Prognostic relevance of metabolic approach in patients with heart failure. Curr. Pharm. Des. 15(8), 883-892 (2009).
10. Kantor PF, Lucien A, Kozak R, Lopaschuk GD: The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ. Res. 86(5), 580-588 (2000).
11. Lopaschuk GD, Stanley WC: Glucose metabolism in the ischemic heart. Circulation 95(2), 313-315 (1997).
12. Bouvy ML, Heerdink ER, Leufkens HG, Hoes AW: Predicting mortality in patients with heart failure: a pragmatic approach. Heart 89(6), 605-609 (2003).
13. Cowie MR, Wood DA, Coats AJ et al.: Survival of patients with a new diagnosis of heart failure: a population based study. Heart 83(5), 505-510 (2000).
14. Scrutinio D, Lagioia R, Ricci A, Clemente M, Boni L, Rizzon P: Prediction of mortality in mild to moderately symptomatic patients with left ventricular dysfunction. The role of the New York Heart Association classification, cardiopulmonary exercise testing, 2D echocardiography and Holter monitoring. Eur. Heart J. 15(8), 1089-1095 (1994).
15. Koglin J, Pehlivanli S, Schwaiblmair M, Vogeser M, Cremer P, vonScheidt W: Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure. J. Am. Coll. Cardiol. 38(7), 1934-1941 (2001).
16. Sato Y, Kita T, Takatsu Y, Kimura T: Biochemical markers of myocyte injury in heart failure. Heart 90(10), 1110-1113 (2004).
17. Belardinelli R, Purcaro A: Effects of trimetazidine on the contractile response of chronically dysfunctional myocardium to low-dose dobutamine in ischemic cardiomyopathy. Eur. Heart J. 22(23), 2164-2170 (2001).
18. Fragasso G, Perseghin G, De Cobelli F et al.: Effects of metabolic modulation by trimetazidine on left ventricular function and phosphocreatine/adenosine triphosphate ratio in patients with heart failure. Eur. Heart J. 27(8), 942-948 (2006).
19. Neubauer S, Horn M, Cramer M et al.: Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy. Circulation 96(7), 2190-2196 (1997).
20. Brottier L, Barat JL, Combe C, Boussens B, Bonnet J, Bricaud H: Therapeutic value of a cardioprotective agent in patients with severe ischemic cardiomyopathy. Eur. Heart J. 11(3), 207-212 (1990).
21. Di Napoli P, Taccardi AA, Barsotti A: Long-term cardioprotective action of trimetazidine and potential effect on the inflammatory process in patients with ischemic dilated cardiomyopathy. Heart 91(2), 161-165 (2005).
22. Vitale C, Wajngaten M, Sposato B et al.: Trimetazidine improves left ventricular function and quality of life in elderly patients with coronary artery disease. Eur. Heart J. 25(20), 1814-1821 (2004).
23. Fragasso G, Piatti PM, Monti L et al.: Short and long-term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy. Am. Heart J. 146(5), E18-E25 (2003).
24. Fragasso G, Palloshi A, Puccetti P et al.: A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure. J. Am. Coll. Cardiol. 48(5), 999-1008 (2006).
25. Tuunanen H, Engblom E, Naum A et al.: Trimetazidine, a metabolic modulator, has cardiac and extracardiac benefits in idiopathic dilated cardiomyopathy. Circulation 118(12), 1250-1258 (2008).
26. Alonso-Martinez JL, Llorente-Diez B, Echegaray-Agara M et al.: C-reactive protein as a predictor of improvement and readmission in heart failure. Eur. J. Heart Fail. 4(3), 331-336 (2002).
27. Di Napoli P, Di Giovanni P, Gaeta MA, D'Apolito G, Barsotti A: Beneficial effects of trimetazidine treatment on exercise tolerance and B-type natriuretic peptide and troponin T plasma levels in patients with stable ischemic cardiomyopathy. Am. Heart J. 154(3), 602-605 (2007).
28. Di Napoli P, Taccardi AA, Barsotti A: Trimetazidine treatment improves myocardial resistance-to-injury during acute decompensation in patients with chronic heart failure. Eur. J. Heart Fail. 8(Suppl.) (Abstract 744) (2009).
29. El-Khady T, El-Sabban K, Gabaly M, Sabry A, Abdel-Hady S: Effects of trimetazidine on myocardial perfusion and the contractile response of chronically dysfunctional myocardium in ischemic cardiomyopathy: a 24-month study. Am. J. Cardiovasc. Drugs 5(4), 271-278 (2005).
30. Di Napoli P, Di Giovanni P, Gaeta MA, Taccardi AA, Barsotti A: Trimetazidine and reduction in mortality and hospitalization in patients with ischemic dilated cardiomyopathy: a post hoc analysis of the Villa Pini d'Abruzzo Trimetazidine Trial. J. Cardiovasc. Pharmacol. 50(5), 585-589 (2007).